Inducible eukaryotic expression system
Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
1. A method for expressing a protein of interest in a cell in a culture medium, wherein the method comprises:
a. growing a eukaryotic cell in a culture medium in the presence of 4-hydroxytamoxifen (“OHT”), wherein the OHT is at a concentration that inhibits expression of a protein of interest in the cell, wherein the cell comprises
i. a gene of interest encoding a protein of interest, wherein the gene of interest is operably linked to an Arc operator, and;
ii. a gene for a regulatory fusion protein, wherein the regulatory fusion protein consists of a ligand-binding domain of an estrogen receptor and an Arc repressor DNA-binding domain; wherein the regulatory fusion protein binds the Arc operator in the presence of the OHT; and wherein the ligand-binding domain of the estrogen receptor comprises either (a) the amino acid sequence of N304 to V595 of SEQ ID NO:8, or (b) the amino acid sequence of N304 to V595 of SEQ ID NO:8 substituted with valine at residue 400, alanine at residue 543, and alanine at residue 544;
b. reducing the concentration of the OHT by dilution; and,
c. expressing the protein of interest.
2. The method according to claim 1 , wherein the protein of interest is an antibody.
3. The method according to claim 1 , wherein the estrogen receptor ligand-binding domain comprises the amino acid sequence of N304 to V595 of SEQ ID NO:8.
4. The method according to claim 1 , wherein the estrogen receptor ligand-binding domain comprises the amino acid sequence of N304 to V595 of SEQ ID NO:8 substituted with valine at residue 400, alanine at residue 543, and alanine at residue 544.